News

On July 29, the 77th American Clinical Chemistry Conference and Clinical Laboratory Medicine Expo (ADLM) was held in McCormick Exhibition Hall in Chicago. ADLM, an important summit in the field of clinical laboratory medicine, is the core stage for displaying cutting-edge technologies and innovative products. It also serves as a bridge for promoting global exchange and cooperation in clinical laboratory medicine. This conference brought together over 20,000 medical experts and industry professionals from approximately 110 countries worldwide.

Autobio was honored to invite key experts from the Chinese Society of Laboratory Medicine and many well-known scholars from the U.S. to its booth to unveil its two star products on display for the first time in the North American market: the fully automated chemiluminescence immunoassay analyzer AutoLumo S900, and the brand new microbial mass spectrometry detection system Autobio T-Series.

Autobio's new product line, launched with the core design concept of "Lab in 0.5 square meters," features two compactly designed products with high performance. The fully automated immunoassay analyzer AutoLumo S900 requires less than 0.5 square meters of laboratory space, yet it can detect at speeds of up to 180 tests per hour. Its floor-to-ceiling ratio of 392T/H/㎡ improves space utilization and detection efficiency, solving the difficult problem of limited laboratory space.

The Autof T series is a fully automated microbial mass spectrometry detection system that is the world's smallest fully automated microbial mass spectrometer. Its volume is 70% smaller than traditional equipment, and its weight is nearly 50% lighter. It also saves 85% of the laboratory table area, making it the perfect solution for tight laboratory spaces. It supports an 18.5-inch full-touch screen and a facial recognition system that allows for intelligent operation and data security management. The Autof T series is customized for small-terminal laboratories. The Autobio T series boasts a comprehensive identification database, encompassing over 1,000 genera and more than 5,200 types of pathogenic microorganisms. This includes Autobio's distinctive filamentous fungi and marine aquatic fungi, providing substantial data support for precise identification.

Following the launch, the Autobio booth experienced a significant increase in visitors. Autobio's international marketing team provided thorough and patient responses, thoroughly explaining the characteristics and clinical value of the products.

The Expo Show floor is an important venue for showcasing the latest research results in the field of clinical laboratory medicine, attracting numerous participants. Three academic abstracts submitted by Autobio were successfully selected and exhibited here. The abstracts focused on drug sensitivity testing, blood vial microbial culture, bacterial in vitro antimicrobial testing, and other cutting-edge technologies. The abstracts covered Autobio's microbiological innovations, practical application cases, and clinical practice experience.

 Autobio's involvement in ADLM 2025 exemplifies its pioneering advancements across multiple domains, thereby establishing a robust foundation for sustained growth in the North American market. Autobio is committed to upholding the spirit of innovation, providing more and better quality products for overseas customers, and working together to promote the popularization and improvement of medical laboratory technology. This will contribute to the cause of human health.